Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Treatment of Type 2 Diabetes: One Extreme to Another

Treatment of Type 2 Diabetes: One Extreme to Another In his article, Dr Havas1 recommends to ignore hyperglycemia in patients with type 2 diabetes mellitus until it becomes symptomatic, and even then he allows the use of metformin only, in addition to diet and exercise. I strongly disagree with his recommendations. I would like to ask Dr Havas if he would prescribe any medicine if a patient has a fasting blood glucose level between 250 and 300 mg/dL (to convert to millimoles per liter, multiply by 0.0555) while following a regimen of diet, exercise, and metformin therapy but is asymptomatic? Roughly what percentage of his patients with diabetes adhere to weight loss and exercise? For how long has he put his strategy into practice, and what kind of results is he seeing on the complications of diabetes in his patients? I find the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial interesting. To me, the message is clear: if you focus on reducing blood glucose level by any means without paying attention to treating insulin resistance, the root cause of type 2 diabetes, you will have disappointing results in the prevention of coronary artery disease (CAD) events because insulin resistance plays a major role in the pathogenesis of CAD. In the ACCORD trial, physicians were allowed to use any combination of drugs. When a thiazolidinedione agent was used, it was mostly rosiglitazone. Compared with rosiglitazone, pioglitazone has been shown to be not only safe2 but also beneficial for CAD.3,4 Dr Havas seems to ignore these excellent studies on pioglitazone. He recommends a strategy that is the opposite extreme of that used in the ACCORD trial, and to me it appears just as harmful, if not more. The results of the ACCORD trial have not changed my practice pattern at all. For a long time, I have been treating type 2 diabetes by treating insulin resistance. I use a 5-component strategy that consists of diet, exercise, stress management, vitamins, and medications, mainly the insulin sensitizers metformin and pioglitazone. I occasionally use sulfonylurea agents, meglitinides, exenatide, or sitagliptin, and only as an add-on to the insulin sensitizers. I almost never use insulin. With this strategy, I achieve an HbA1c level of less than 6.5% in the majority of my patients with type 2 diabetes. I rarely encounter hypoglycemia. Severe hypoglycemia due to insulin and sulfonylurea agents is one of the plausible explanations for the unexpected increase in cardiovascular disease events in the ACCORD study. In contrast to the ACCORD findings, I see a notable decrease in cardiovascular disease events. Other complications of type 2 diabetes are also remarkably decreased. Correspondence: Dr Zaidi, Department of Internal Medicine, Jamila Diabetes and Endocrine Medical Center, 1429 E Thousand Oaks Blvd, Ste 105, Thousand Oaks, CA 91362 (sjzaidi@verizon.net). References 1. Havas S The ACCORD trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch Intern Med 2009;169 (2) 150- 154PubMedGoogle ScholarCrossref 2. Lincoff AMWolski KNicholls SJNissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298 (10) 1180- 1188PubMedGoogle ScholarCrossref 3. Dormandy JACharbonnel BEckland DJ et al. PROactive investigators, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366 (9493) 1279- 1289PubMedGoogle ScholarCrossref 4. Nissen SENicholls SJWolski L et al. PERISCOPE Investigators, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 2008;299 (13) 1561- 1573PubMedGoogle ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Treatment of Type 2 Diabetes: One Extreme to Another

Archives of Internal Medicine , Volume 169 (13) – Jul 13, 2009

Loading next page...
 
/lp/american-medical-association/treatment-of-type-2-diabetes-one-extreme-to-another-YrQJxvX11e
Publisher
American Medical Association
Copyright
Copyright © 2009 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinternmed.2009.186
Publisher site
See Article on Publisher Site

Abstract

In his article, Dr Havas1 recommends to ignore hyperglycemia in patients with type 2 diabetes mellitus until it becomes symptomatic, and even then he allows the use of metformin only, in addition to diet and exercise. I strongly disagree with his recommendations. I would like to ask Dr Havas if he would prescribe any medicine if a patient has a fasting blood glucose level between 250 and 300 mg/dL (to convert to millimoles per liter, multiply by 0.0555) while following a regimen of diet, exercise, and metformin therapy but is asymptomatic? Roughly what percentage of his patients with diabetes adhere to weight loss and exercise? For how long has he put his strategy into practice, and what kind of results is he seeing on the complications of diabetes in his patients? I find the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial interesting. To me, the message is clear: if you focus on reducing blood glucose level by any means without paying attention to treating insulin resistance, the root cause of type 2 diabetes, you will have disappointing results in the prevention of coronary artery disease (CAD) events because insulin resistance plays a major role in the pathogenesis of CAD. In the ACCORD trial, physicians were allowed to use any combination of drugs. When a thiazolidinedione agent was used, it was mostly rosiglitazone. Compared with rosiglitazone, pioglitazone has been shown to be not only safe2 but also beneficial for CAD.3,4 Dr Havas seems to ignore these excellent studies on pioglitazone. He recommends a strategy that is the opposite extreme of that used in the ACCORD trial, and to me it appears just as harmful, if not more. The results of the ACCORD trial have not changed my practice pattern at all. For a long time, I have been treating type 2 diabetes by treating insulin resistance. I use a 5-component strategy that consists of diet, exercise, stress management, vitamins, and medications, mainly the insulin sensitizers metformin and pioglitazone. I occasionally use sulfonylurea agents, meglitinides, exenatide, or sitagliptin, and only as an add-on to the insulin sensitizers. I almost never use insulin. With this strategy, I achieve an HbA1c level of less than 6.5% in the majority of my patients with type 2 diabetes. I rarely encounter hypoglycemia. Severe hypoglycemia due to insulin and sulfonylurea agents is one of the plausible explanations for the unexpected increase in cardiovascular disease events in the ACCORD study. In contrast to the ACCORD findings, I see a notable decrease in cardiovascular disease events. Other complications of type 2 diabetes are also remarkably decreased. Correspondence: Dr Zaidi, Department of Internal Medicine, Jamila Diabetes and Endocrine Medical Center, 1429 E Thousand Oaks Blvd, Ste 105, Thousand Oaks, CA 91362 (sjzaidi@verizon.net). References 1. Havas S The ACCORD trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch Intern Med 2009;169 (2) 150- 154PubMedGoogle ScholarCrossref 2. Lincoff AMWolski KNicholls SJNissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298 (10) 1180- 1188PubMedGoogle ScholarCrossref 3. Dormandy JACharbonnel BEckland DJ et al. PROactive investigators, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366 (9493) 1279- 1289PubMedGoogle ScholarCrossref 4. Nissen SENicholls SJWolski L et al. PERISCOPE Investigators, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 2008;299 (13) 1561- 1573PubMedGoogle ScholarCrossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jul 13, 2009

Keywords: diabetes mellitus, type 2

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month